Shin Nippon Biomedical Laboratories, Ltd. (SBLOF)
OTCMKTS · Delayed Price · Currency is USD
9.36
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
SBLOF Revenue
Shin Nippon Biomedical Laboratories had revenue of 6.43B JPY in the quarter ending December 31, 2025, a decrease of -33.90%. This brings the company's revenue in the last twelve months to 31.37B, up 2.19% year-over-year. In the fiscal year ending March 31, 2025, Shin Nippon Biomedical Laboratories had annual revenue of 32.41B with 22.54% growth.
Revenue (ttm)
31.37B JPY
Revenue Growth
+2.19%
P/S Ratio
2.34
Revenue / Employee
20.49M JPY
Employees
1,531
Market Cap
467.62M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 32.41B | 5.96B | 22.54% |
| Mar 31, 2024 | 26.45B | 1.36B | 5.42% |
| Mar 31, 2023 | 25.09B | 7.34B | 41.37% |
| Mar 31, 2022 | 17.75B | 2.64B | 17.46% |
| Mar 31, 2021 | 15.11B | 549.00M | 3.77% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Global Cord Blood | 196.10M |
| Centogene | 53.65M |
| Bioqual | 46.54M |
| Interpace Biosciences | 41.92M |
| Psychemedics | 19.69M |
| China New Energy Group Company | 12.51M |
| Aspira Women's Health | 9.34M |
| Longduoduo Company | 2.72M |